统计运动建模用于稳健评估局部晚期前列腺癌根治性放疗后临床实际累积剂量分布
本研究在局部晚期前列腺癌剂量递增试验中,基于213次CT扫描和5年随访数据,采用统计剂量累积与DVH相加两种方法估算实际递送剂量并与计划剂量比较。结果显示21例中12例前列腺CTV67.5存在剂量不足,实际递送剂量递增(D98%)平均为73.9GyEQD2(范围68.3-78.7GyEQD2),超过半数患者未接受到计划的剂量递增。
要点
- 21例中有12例在CTV67.5不同位置出现剂量不足。
- 实际递送剂量递增(D98%)平均为73.9GyEQD2(范围68.3-78.7GyEQD2)。
- 有复发(n=8)与无复发(n=13)患者的累积D98%无显著差异(p>0.05)。
核心结论
- 计划的剂量递增未被执行到超过半数的患者。
- 鉴于低毒性特征,在这些患者中应更好地优先考虑前列腺靶区(CTV67.5)的稳健性。
- 由于随机器官运动与剂量矩阵的相互作用,剂量累积法对递送剂量的估计较不保守。
研究设计与样本
- 基于剂量递增试验的统计分析,处方剂量递增至前列腺为67.5 Gy/25次,假设α/β=1.5时相当于81GyEQD2。
- 21例患者设三个靶区(CTV67.5+2 mm、CTV60+5 mm、CTV50+10 mm),采用同步整合推量技术照射。
- 分析基于213次CT扫描和5年随访。
- 统计剂量累积法基于计划剂量和轮廓配准的形变矢量场模拟10000种可能疗程;DVH相加法在重复CT上重新计算剂量并估算中位D98%/EUD。
主要发现
- 计划剂量与累积剂量的差异主要见于CTV67.5,12/21例患者在前列腺不同位置发现剂量不足。
- 实际递送剂量递增(D98%)平均为73.9GyEQD2(范围68.3-78.7GyEQD2)。
- 有复发(n=8)与无复发(n=13)患者的累积D98%无显著差异(p>0.05)。
- 统计剂量累积法与DVH相加法的平均D98%/EUD在CTV60、CTV50、直肠和膀胱中显著不同,但在CTV67.5中无显著差异。
关键数值与推荐
- 处方剂量递增至前列腺为67.5 Gy/25次,假设α/β=1.5时相当于81GyEQD2。
- 三个靶区分别为CTV67.5+2 mm、CTV60+5 mm、CTV50+10 mm。
- 实际递送剂量递增(D98%)平均为73.9GyEQD2(范围68.3-78.7GyEQD2)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Planned doses are used as surrogate for the actually delivered dose in radiotherapy. We have estimated the delivered dose in a dose-escalation trial of locally advanced prostate cancer by statistical dose-accumulation and by DVH-summation, and compared to planned dose. MATERIALS AND METHOD: Prescribed dose-escalation to the prostate was 67.5 Gy/25fr., corresponding to 81GyEQD2 assuming α/β = 1.5. The 21 patients had three targets (i.e. CTV67.5 + 2 mm, CTV60 + 5 mm, CTV50 + 10 mm) irradiated by a simultaneous-integrated-boost technique. Analysis was based on 213 CT scans and 5-years of follow-up. For statistical dose-accumulation, we modelled 10000 possible treatment courses based on planned dose and deformation-vector-fields from contour-based registration. For DVH-summation we recalculated dose on repeat-CTs and estimated median D98%/EUD. Groups with/without disease recurrence were compared. RESULTS: Discrepancies between planned and accumulated dose were mostly seen for CTV67.5, where under-dosage was found at different locations in the prostate in 12/21 patients. Delivered dose-escalation (D98%) was on average 73.9GyEQD2 (range: 68.3-78.7GyEQD2). No significant difference in accumulated-D98% was found in patients with (n = 8) and without (n = 13) recurrence (p > 0.05). Average D98%/EUD with statistical dose-accumulation vs DVH-summation was significantly different in CTV60, CTV50, rectum and bladder but not in CTV67.5. CONCLUSION: The planned dose escalation was not received by more than half-of-the patients. Robustness of the prostate target (CTV67.5) should therefore be better prioritized in these patients given the low toxicity profile. Estimates of delivered dose were less conservative for dose-accumulation due to interaction of random organ motion with the dose matrix.
引用
- Hysing LB, Ekanger C, Zolnay Á, et al. Statistical motion modelling for robust evaluation of clinically delivered accumulated dose distributions after curative radiotherapy of locally advanced prostate cancer. Radiother Oncol. 2018. PMID: 29941300. doi:10.1016/j.radonc.2018.06.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。